3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Breast Neoplasms
12
Neoplasm Metastasis
6
Glioblastoma
4
Triple Negative Breast Neoplasms
3
Brain Neoplasms
3
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasms
2
Hereditary Sensory and Autonomic Neuropathies
2
Carcinoma, Non-Small-Cell Lung
2
Treatment for Metastatic or Locally Advanced Cervical Cancer
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Recurrence
1
Pre-menopausal Breast Cancer
1
Non-Small Cell Lunch Cancer
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Locally Advanced Solid Tumor
1
Leukemia, Myeloid, Acute
1
Hematologic Neoplasms
1
Head and Neck Neoplasms
1
Gliosarcoma
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Interventions
Azacitidine
14
venetoclax
10
AP 1903 reagent
7
Rituximab
6
Dexamethasone
6
Itraconazole
5
Cytarabine
5
Bortezomib
5
fludarabine
4
fedratinib
4
belinostat
4
Nivolumab
4
Lenalidomide
4
Imatinib Mesylate
4
Daunorubicin
4
ARQ531
4
pomalidomide
3
ibrutinib
3
daratumumab
3
cc-486
3
angiotensin I (1-7)
3
Standard of Care
3
GSK2110183
3
Cyclophosphamide
3
zanubrutinib
2
tosedostat
2
tazemetostat
2
tanespimycin
2
talquetamab
2
tafasitamab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Hematologic Neoplasms
×
NVP-BKM120
×
Clear all
NCT01833169
2018-10-19
SIGNATURE
Novartis
Phase 2
Completed
146 enrolled
17 charts